Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T A Larson

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Therapeutic Drug Monitoring|January 1, 1987
Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassayB E Bleske, T A Larson, J C Rotschafer
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 10, 2000
Practice models used by pharmacists in rural Minnesota to obtain Medicare reimbursementT A Larson, D L Uden, R S Hadsall
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 1996
Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaineT A Larson, D L Uden, C G Schilling
Social Work in Health Care|January 11, 1976
The status of graduate-level social workers teaching in medical schoolsR M Grinell, N S Kyte, S Hunter, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1992
Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic modelK Vance-Bryan, T A Larson, J C Rotschafer, et al.
Oncogene|September 7, 1995
The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic miceR C Larson, H Osada, T A Larson, et al.
Minnesota Medicine|June 26, 1998
Minnesota's new Rural Health SchoolB J Crouse, D Block, B Elliott, et al.
Infection and Immunity|July 1, 1994
Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannanD C Houpt, G S Pfrommer, B J Young, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1990
Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelM W Garrison, K Vance-Bryan, T A Larson, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1982
Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjectsL R Peterson, D N Gerding, L L Van Etta, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Therapeutic Drug Monitoring|January 1, 1987
Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by enzyme immunoassay and fluorescence polarization immunoassayB E Bleske, T A Larson, J C Rotschafer
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 10, 2000
Practice models used by pharmacists in rural Minnesota to obtain Medicare reimbursementT A Larson, D L Uden, R S Hadsall
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 15, 1996
Stability of epinephrine hydrochloride in an extemporaneously compounded topical anesthetic solution of lidocaine, racepinephrine, and tetracaineT A Larson, D L Uden, C G Schilling
Social Work in Health Care|January 11, 1976
The status of graduate-level social workers teaching in medical schoolsR M Grinell, N S Kyte, S Hunter, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1992
Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic modelK Vance-Bryan, T A Larson, J C Rotschafer, et al.
Oncogene|September 7, 1995
The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic miceR C Larson, H Osada, T A Larson, et al.
Minnesota Medicine|June 26, 1998
Minnesota's new Rural Health SchoolB J Crouse, D Block, B Elliott, et al.
Infection and Immunity|July 1, 1994
Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannanD C Houpt, G S Pfrommer, B J Young, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1990
Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelM W Garrison, K Vance-Bryan, T A Larson, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1982
Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjectsL R Peterson, D N Gerding, L L Van Etta, et al.
Pageof 4